Emerging Technologies

Do microbiomes cause chronic diseases?

Jon Turney
Our Impact
What's the World Economic Forum doing to accelerate action on Emerging Technologies?
A hand holding a looking glass by a lake
Crowdsource Innovation
Get involved with our crowdsourced digital platform to deliver impact at scale
Stay up to date:

Future of Global Health and Healthcare

Human microbiomes are ecosystems in their own right. The way microbiomes function, especially in the gut, brings important benefits to digestion, nutrition and immune function. Microbiome disruption has been linked with a growing list of chronic diseases such as inflammatory bowel diseases (IBD), rheumatoid arthritis and multiple sclerosis—even depression and anxiety. But to what extent is this link to chronic disease a causal one?

Some, like Stanford University researcher Jason Sonnenburg, believe that  modern eating habits, notably decrease in consumption of dietary fibres, reduce microbial production of certain metabolites—short-chain fatty acids. This, he argues, “results in more simmering inflammation which, over decades, leads to most of the chronic diseases that plague the modern world”.

The evidence can be hard to read, however, and correlation between microbial shifts and disease does not establish that one causes the other. A paper from Harvard published last month, for example, showed that a drop in the diversity of microbes in the gut precedes appearance of Type 1 diabetes in children. The fact that the children under study were known to be genetically susceptible to diabetes complicates interpretation, however—microbial shifts and destruction of insulin-producing cells could both be encouraged by other factors, for example.

Others caution against what some have dubbed “microbiomania”. Epidemiologist Bill Hanage, also of Harvard, sees current results as  suggestive, no more. “There is very good evidence that the microbiome could be involved in a lot of things. There is very little evidence that it is definitely one of the things—let alone the most important thing—influencing almost any of them.”

He grants that there is good reason to believe that the microbiome is involved in development of IBD, for example. Tests on mice, in fact, seem to back this intuition. But getting a clear picture of what could benefit patients is still difficult. “IBD is a variable disease, which may well have multiple causes. This leads to problems with inclusion criteria. An intervention might work well in one setting, and not others,” says Mr Hanage.

The complexity of the microbiome means the number of things that might cause a particular effect, and the number of ways in which it could do so, increases significantly. Clear evidence of positive effects from microbial treatments, such as have been shown with total microbiome transplants for patients suffering from Clostridium difficile infections, will not be available to us for other conditions for some time.

The safest conclusion for now is that much more detailed research is required—research of the kind that will be discussed this week at the fifth International Human Microbiome Congress in Luxembourg. John Cryan of University College in Cork, Ireland, is a strong advocate for the importance of microbiome studies in many conditions, including some affecting the brain—where chains of cause and effect are likely to be longer. But for now, he urges, “we need to get away from the hype into the hard science”.

This article is published in collaboration with GE Look Ahead. Publication does not imply endorsement of views by the World Economic Forum.

To keep up with the Agenda subscribe to our weekly newsletter.

Author: Jon Turney writes for GE Look Ahead. 

Image: A researcher uses a microscope after a laser bio- 3D printing of human cells in the laboratory Biotis at INSERM. REUTERS/Regis Duvignau

Don't miss any update on this topic

Create a free account and access your personalized content collection with our latest publications and analyses.

Sign up for free

License and Republishing

World Economic Forum articles may be republished in accordance with the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Public License, and in accordance with our Terms of Use.

The views expressed in this article are those of the author alone and not the World Economic Forum.

World Economic Forum logo
Global Agenda

The Agenda Weekly

A weekly update of the most important issues driving the global agenda

Subscribe today

You can unsubscribe at any time using the link in our emails. For more details, review our privacy policy.

How Europe can harness digitalization to become a leader in business AI

Christian Klein

April 24, 2024

About Us



Partners & Members

  • Join Us

Language Editions

Privacy Policy & Terms of Service

© 2024 World Economic Forum